Add to ORKGNiaraparib (Zejula®) is a poly(ADP-ribose) polymerase inhibitor (PARPi) whch is approved in Europe for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to first line platinum –based chemotherapy or with platinum-sensitive relapsed ovarian cancer, in both cases in the overall population, regardless of BRCA or HRD status. In PRIMA and NOVA trial niraparib significantly extended progression free survival both in homologous recombination deficiency positive and overall trial population. Haematological events were the most commonly occurring and could be managed with monitoring and dosage reduction or interruption. A weight – and platelet count –based individualised dosage regiment improve haematological...
ImportancePatients with recurrent ovarian carcinoma frequently develop resistance to platinum-based ...
Ovarian cancer being asymptomatic is leading to late diagnosis resulting in increased death rate wor...
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA...
Introducing PARP inhibitors maintenance therapy into clinical practice significantly improved treatm...
Introducing PARP inhibitors maintenance therapy into clinical practice significantly improved treatm...
Niraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibi...
Niraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibi...
Background Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhib...
BACKGROUND Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), h...
Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved...
INTRODUCTION: Ovarian cancer is a disease with a propensity to recur despite dramatic responses to i...
BACKGROUND: Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), h...
Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved...
Niraparib (Zejula®), poly (ADP-ribose) polymerase inhibitor (PARP) jest zarejestrowany do leczenia p...
ImportancePatients with recurrent ovarian carcinoma frequently develop resistance to platinum-based ...
Ovarian cancer being asymptomatic is leading to late diagnosis resulting in increased death rate wor...
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA...
Introducing PARP inhibitors maintenance therapy into clinical practice significantly improved treatm...
Introducing PARP inhibitors maintenance therapy into clinical practice significantly improved treatm...
Niraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibi...
Niraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibi...
Background Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhib...
BACKGROUND Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), h...
Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved...
INTRODUCTION: Ovarian cancer is a disease with a propensity to recur despite dramatic responses to i...
BACKGROUND: Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), h...
Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved...
Niraparib (Zejula®), poly (ADP-ribose) polymerase inhibitor (PARP) jest zarejestrowany do leczenia p...
ImportancePatients with recurrent ovarian carcinoma frequently develop resistance to platinum-based ...
Ovarian cancer being asymptomatic is leading to late diagnosis resulting in increased death rate wor...
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA...